Cargando…
The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease
Alzheimer’s disease (AD) is a chronic neurodegenerative disease, which is associated with learning and memory impairment in the elderly. Recent studies have found that treating AD in the way of chromatin remodeling via histone acetylation is a promising therapeutic regimen. In a number of recent stu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504819/ https://www.ncbi.nlm.nih.gov/pubmed/28702178 http://dx.doi.org/10.1186/s40035-017-0089-1 |
_version_ | 1783249355152556032 |
---|---|
author | Yang, Shuang-shuang Zhang, Rui Wang, Gang Zhang, Yong-fang |
author_facet | Yang, Shuang-shuang Zhang, Rui Wang, Gang Zhang, Yong-fang |
author_sort | Yang, Shuang-shuang |
collection | PubMed |
description | Alzheimer’s disease (AD) is a chronic neurodegenerative disease, which is associated with learning and memory impairment in the elderly. Recent studies have found that treating AD in the way of chromatin remodeling via histone acetylation is a promising therapeutic regimen. In a number of recent studies, inhibitors of histone deacetylase (HDACs) have been found to be a novel promising therapeutic agents for neurological disorders, particularly for AD and other neurodegenerative diseases. Although HDAC inhibitors have the ability to ameliorate cognitive impairment, successful treatments in the classic AD animal model are rarely translated into clinical trials. As for the reduction of unwanted side effects, the development of HDAC inhibitors with increased isoform selectivity or seeking other directions is a key issue that needs to be addressed. The review focused on literatures on epigenetic mechanisms in recent years, especially on histone acetylation in terms of the enhancement of specificity, efficacy and avoiding side effects for treating AD. |
format | Online Article Text |
id | pubmed-5504819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55048192017-07-12 The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease Yang, Shuang-shuang Zhang, Rui Wang, Gang Zhang, Yong-fang Transl Neurodegener Review Alzheimer’s disease (AD) is a chronic neurodegenerative disease, which is associated with learning and memory impairment in the elderly. Recent studies have found that treating AD in the way of chromatin remodeling via histone acetylation is a promising therapeutic regimen. In a number of recent studies, inhibitors of histone deacetylase (HDACs) have been found to be a novel promising therapeutic agents for neurological disorders, particularly for AD and other neurodegenerative diseases. Although HDAC inhibitors have the ability to ameliorate cognitive impairment, successful treatments in the classic AD animal model are rarely translated into clinical trials. As for the reduction of unwanted side effects, the development of HDAC inhibitors with increased isoform selectivity or seeking other directions is a key issue that needs to be addressed. The review focused on literatures on epigenetic mechanisms in recent years, especially on histone acetylation in terms of the enhancement of specificity, efficacy and avoiding side effects for treating AD. BioMed Central 2017-07-10 /pmc/articles/PMC5504819/ /pubmed/28702178 http://dx.doi.org/10.1186/s40035-017-0089-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Yang, Shuang-shuang Zhang, Rui Wang, Gang Zhang, Yong-fang The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease |
title | The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease |
title_full | The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease |
title_fullStr | The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease |
title_full_unstemmed | The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease |
title_short | The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease |
title_sort | development prospection of hdac inhibitors as a potential therapeutic direction in alzheimer’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504819/ https://www.ncbi.nlm.nih.gov/pubmed/28702178 http://dx.doi.org/10.1186/s40035-017-0089-1 |
work_keys_str_mv | AT yangshuangshuang thedevelopmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease AT zhangrui thedevelopmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease AT wanggang thedevelopmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease AT zhangyongfang thedevelopmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease AT yangshuangshuang developmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease AT zhangrui developmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease AT wanggang developmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease AT zhangyongfang developmentprospectionofhdacinhibitorsasapotentialtherapeuticdirectioninalzheimersdisease |